9969 Share Price Performance
HK$13.54
-4.27 (-23.98%)
31.0% undervalued intrinsic discount
HK$19.62
Fair Value
Price HK$13.54
AnalystConsensusTarget HK$19.62
AnalystLowTarget HK$17.24
AnalystHighTarget HK$22.19
Fair ValueHK$19.62
Share Pricen/a
InnoCare Pharma Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
9969 Community Narratives
AN
Fair Value
·Fair Value HK$19.62 31.0% undervalued intrinsic discount
Analysts Lift InnoCare Pharma Target Price as Margins and Revenue Outlook Improve
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value HK$17.24 21.4% undervalued intrinsic discount
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value HK$22.19 39.0% undervalued intrinsic discount
Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
InnoCare Pharma
31.0% undervalued intrinsic discount
Analysts Lift InnoCare Pharma Target Price as Margins and Revenue Outlook Improve
View narrativeAN
Updated 11 Jun
InnoCare Pharma
39.0% undervalued intrinsic discount
Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
View narrativeAN
Updated 1 May
InnoCare Pharma
21.4% undervalued intrinsic discount
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
View narrativeAN
Updated 1 Apr
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
9969: Autoimmune Data Readouts And Licensing Momentum Will Drive Future Upside Potential
Fair Value: HK$19.62 31.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
9969: Late Stage Autoimmune Pipeline Progress Will Drive Repricing
Fair Value: HK$22.19 39.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
9969: Autoimmune And Pediatric Oncology Pipeline Progress Will Support Undervalued Shares
Fair Value: HK$17.24 21.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
InnoCare Pharma Limited Key Details
About 9969
- Founded
- 2015
- Employees
- 1388
- CEO
- WebsiteView website
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
